← Back to Screener
Equillium, Inc. Common Stock (EQ)
Price$2.01
Favorite Metrics
Price vs S&P 500 (26W)44.24%
Price vs S&P 500 (4W)-13.25%
Market Capitalization$127.09M
All Metrics
Book Value / Share (Quarterly)$0.47
P/TBV (Annual)0.56x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.37
Price vs S&P 500 (YTD)28.12%
Net Profit Margin (TTM)-19.63%
EPS (TTM)$-0.51
10-Day Avg Trading Volume0.38M
EPS Excl Extra (TTM)$-0.51
EPS (Annual)$-0.39
ROI (Annual)-78.32%
Net Profit Margin (5Y Avg)-1079.66%
Cash / Share (Quarterly)$0.49
ROA (Last FY)-70.24%
Revenue Growth TTM (YoY)-90.43%
EBITD / Share (TTM)$-0.40
ROE (5Y Avg)-86.78%
Operating Margin (TTM)-20.12%
Cash Flow / Share (Annual)$-0.37
P/B Ratio4.44x
P/B Ratio (Quarterly)3.30x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)2.36x
Net Interest Coverage (TTM)-98.10x
ROA (TTM)-93.79%
EPS Incl Extra (Annual)$-0.39
Current Ratio (Annual)10.58x
Quick Ratio (Quarterly)10.43x
3-Month Avg Trading Volume0.62M
52-Week Price Return365.91%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.69
P/S Ratio (Annual)3.09x
Asset Turnover (Annual)1.60x
52-Week High$2.70
Operating Margin (5Y Avg)-1045.45%
EPS Excl Extra (Annual)$-0.39
CapEx CAGR (5Y)-24.83%
26-Week Price Return52.99%
Quick Ratio (Annual)10.43x
13-Week Price Return78.26%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)10.58x
Enterprise Value$96.808
Asset Turnover (TTM)1.12x
Book Value / Share Growth (5Y)-30.27%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-18.75%
Cash / Share (Annual)$0.49
3-Month Return Std Dev93.50%
Net Income / Employee (TTM)$-1
ROE (Last FY)-78.32%
Net Interest Coverage (Annual)-96.56x
EPS Basic Excl Extra (Annual)$-0.39
P/FCF (TTM)1.55x
Receivables Turnover (TTM)22.01x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.51
ROI (TTM)-119.19%
P/S Ratio (TTM)3.09x
Pretax Margin (5Y Avg)-1079.66%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.93
Price vs S&P 500 (52W)330.81%
Year-to-Date Return32.26%
5-Day Price Return20.59%
EPS Normalized (Annual)$-0.39
ROA (5Y Avg)-50.69%
Net Profit Margin (Annual)-19.63%
Month-to-Date Return2.50%
Cash Flow / Share (TTM)$-0.23
EBITD / Share (Annual)$-0.40
Operating Margin (Annual)-20.12%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-76.66%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.51
P/TBV (Quarterly)0.74x
P/B Ratio (Annual)3.30x
Pretax Margin (TTM)-18.75%
Book Value / Share (Annual)$0.47
Price vs S&P 500 (13W)75.40%
Beta1.76x
Revenue / Share (TTM)$0.00
ROE (TTM)-119.19%
52-Week Low$0.27
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.20
4.20
4.27
4.25
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
EQEquillium, Inc. Common Stock | 3.09x | -90.43% | — | — | $2.01 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Equillium is a clinical-stage biotechnology company developing novel immunotherapies for severe autoimmune and inflammatory disorders. Its lead candidate, Itolizumab (EQ001), is an anti-CD6 monoclonal antibody designed to modulate pathogenic immune responses while preserving regulatory T cells. The company plans to commercialize its pipeline through partnerships, independent development, or strategic transactions. Additional candidates include EQ101 and EQ302.